Results 211 to 220 of about 76,229 (261)

Radiolabelled Agents for PET Imaging of Tumor Hypoxia

Current Medicinal Chemistry, 2012
Hypoxia has been observed in a variety of human tumor types and evaluating tumor hypoxia is important because it increases resistance to radiotherapy and chemotherapy by inducing proteomic change that allow the tumor cell to survive in their hypoxic environment.
H, Kurihara, N, Honda, Y, Kono, Y, Arai
openaire   +2 more sources

New PET imaging agents in the management of solid cancers

Current Opinion in Oncology, 2012
(18)F-fluoro-2-deoxy-D-glucose PET-computed tomography (CT) has a major clinical impact in oncology not only for diagnostics but also for staging, response assessment, and relapse detection. However, several other PET tracers are needed for a more complete molecular characterization of cancers which has great importance in the era of individualized ...
Garcia, Camilo, Gebhart, Géraldine, Flamen, Patrick   +2 more
openaire   +3 more sources

AAZTA: An Ideal Chelating Agent for the Development of ⁴⁴Sc PET Imaging Agents

Angewandte Chemie International Edition, 2017
AbstractUnprecedented fast and efficient complexation of ScIII was demonstrated with the chelating agent AAZTA (AAZTA=1,4‐bis(carboxymethyl)‐6‐[bis(carboxymethyl)]amino‐6‐methylperhydro‐1,4‐diazepine) under mild experimental conditions. The robustness of the 44Sc(AAZTA)− chelate and conjugated biomolecules thereof is further shown by in vivo PET ...
Gábor Nagy, Dezső Szikra, György Trencsényi, Anikó Fekete, Ildikó Garai, Arianna M. Giani, Roberto Negri, Norberto Masciocchi, Alessandro Maiocchi, Fulvio Uggeri, Imre Tóth, Silvio Aime, Giovanni B. Giovenzana, Zsolt Baranyai   +13 more
openaire   +4 more sources

PET Imaging Agents for Alzheimer’s Disease

2017
In the past four decades, PET (positron emission tomography) imaging has been developed into a common diagnostic tool. After an i.v. injection of a small amount of radioactive probe, PET images are taken based on the decay of short-lived positron-emitting isotopes.
Seok Rye Choi, Karl Ploessl, Lin Zhu, Hank F. Kung   +3 more
openaire   +1 more source

55Cobalt complexes with pendant carbohydrates as potential PET imaging agents

Applied Radiation and Isotopes, 2007
Bis-ligand cobalt(II) complexes of four 3-hydroxy-4-pyridinone ligands with pendant carbohydrates were synthesized and examined for their potential as radiopharmaceuticals. Non-radioactive complexes were prepared on the macroscopic scale and characterized by elemental analysis, mass spectrometry, IR and UV/visible spectroscopy.
Cara L, Ferreira, Suzanne, Lapi, Jennifer, Steele, David E, Green, Thomas J, Ruth, Michael J, Adam, Chris, Orvig   +6 more
openaire   +2 more sources

PET imaging agents targeting macrophage surface receptors

Chinese Science Bulletin, 2019
Inflammation is a defense reaction produced by the body to protect against pathogenic factors, whereas the persistent state of inflammation or excessive inflammatory response is the pathological basis of many afflictions. As the main type of activated inflammatory cells in the inflammatory environment, macrophages exert great influence on the outcome ...
Zhequan Fu, Hongcheng Shi, Dengfeng Cheng   +2 more
openaire   +1 more source

Radiolabelling and evaluation of a novel sulfoxide as a PET imaging agent for tumor hypoxia

Nuclear Medicine and Biology, 2014
[¹⁸F]FMISO is the most widely validated PET radiotracer for imaging hypoxic tissue. However, as a result of the pharmacokinetics of [¹⁸F]FMISO a 2h wait between tracer administration and patient scanning is required for optimal image acquisition. In order to develop hypoxia imaging agents with faster kinetics, we have synthesised and evaluated several ...
Evelyn, Laurens, Shinn Dee, Yeoh, Angela, Rigopoulos, Diana, Cao, Glenn A, Cartwright, Graeme J, O'Keefe, Henri J, Tochon-Danguy, Jonathan M, White, Andrew M, Scott, Uwe, Ackermann   +9 more
openaire   +2 more sources

Radiolabelling and evaluation of novel haloethylsulfoxides as PET imaging agents for tumor hypoxia

Nuclear Medicine and Biology, 2012
The significance of imaging hypoxia with the PET ligand [(18)F]FMISO has been demonstrated in a variety of cancers. However, the slow kinetics of [(18)F]FMISO require a 2-h delay between tracer administration and patient scanning. Labelled chloroethyl sulfoxides have shown faster kinetics and higher contrast than [(18)F]FMISO in a rat model of ischemic
Evelyn, Laurens, Shinn Dee, Yeoh, Angela, Rigopoulos, Diana, Cao, Glenn A, Cartwright, Graeme J, O'Keefe, Henri J, Tochon-Danguy, Jonathan M, White, Andrew M, Scott, Uwe, Ackermann   +9 more
openaire   +2 more sources

Microwave Accelerated Synthesis of PET Image Contrast Agents for AD Research

Current Alzheimer Research, 2010
Positron emission tomography (PET) imaging of Alzheimer's Disease (AD) offers the potential to provide early onset diagnosis and subsequent intervention, including guided treatment regimens. One of the restricting factors in clinical application of PET technology is the limited availability of radioligands with affinity to specific targets of interest.
A E, Kallmerten, G B, Jones
openaire   +2 more sources

Development of brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease

2019
Neuroinflammation is thought to play a key role in the development and progression of neurodegenerative diseases such as Alzheimer's disease. Positron emission tomography (PET) is an in vivo imaging technique capable of studying the biochemical processes which provide the molecular basis of disease.
Janssen, Bieneke, Mach, Robert H.
openaire   +3 more sources